What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down

2 hours ago 1

Seena Hassouna, The Motley Fool

Wed, March 18, 2026 astatine 10:41 AM CDT 4 min read

On February 17, 2026, VR Adviser, LLC disclosed successful a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix (NASDAQ:OCUL), an estimated $71.01 cardinal commercialized based connected quarterly mean pricing.

VR Adviser, LLC Sold 5,845,915 shares of Ocular Therapeutix; estimated transaction worth of $70.96 cardinal based connected quarterly mean price.
The quarter-end worth of the presumption dropped by $65.05 million, reflecting some trading and Ocular Therapeutix stock terms changes.
The transaction represented 3.51% of VR Adviser, LLC’s reportable assets nether management.
Following the sale, VR Adviser, LLC held 7,315,547 shares ($88.81 million)
Ocular Therapeutix present accounts for 4.39% of money AUM, placing it extracurricular the fund's apical 5 holdings

According to a February 17, 2026, SEC filing, VR Adviser, LLC reduced its presumption successful Ocular Therapeutix (NASDAQ:OCUL) by 5,845,915 shares during the 4th quarter. The estimated transaction worth is $70.96 cardinal based connected the mean closing stock terms for the quarter. The quarter-end worth of the presumption fell by $65.05 million, reflecting some the merchantability and changes successful the stock’s terms during the period.

VR Adviser, LLC’s merchantability brought its Ocular Therapeutix involvement to 4.3868% of reportable AUM arsenic of December 31, 2025
Top holdings aft the filing:
- NASDAQ:APGE: $641,075,869 (31.7% of AUM)
- NASDAQ:ORKA: $125,738,853 (6.2% of AUM)
- NASDAQ:VRDN: $120,829,904 (6.0% of AUM)
- NASDAQ:SYRE: $120,735,276 (6.0% of AUM)
- NASDAQ:KALV: $108,673,108 (5.4% of AUM)
As of February 17, 2026, shares of Ocular Therapeutix were priced astatine $6.99, down 3.98% implicit the past year, underperforming the S&P 500 by 15.90 percent points.

Metric

Value

Price (as of marketplace adjacent February 17, 2026)	$6.99
Market capitalization	$1.50 billion
Revenue (TTM)	$51.95 million
Net income (TTM)	($265.94 million)

Ocular Therapeutix develops and commercializes ophthalmic therapies, including marketed products specified arsenic ReSure Sealant and DEXTENZA, and is advancing a pipeline of cause transportation implants for retinal diseases, glaucoma, and adust eye.
The institution generates gross done merchandise income and strategical collaborations, leveraging its proprietary bioresorbable hydrogel exertion for sustained cause transportation successful ophthalmology.
Primary customers see ophthalmologists, oculus attraction centers, and healthcare providers treating ocular diseases, with a absorption connected some U.S. and planetary markets done nonstop income and licensing partnerships.

Ocular Therapeutix is simply a clinical-stage biopharmaceutical institution specializing successful innovative cause transportation solutions for oculus diseases. The institution combines proprietary hydrogel exertion with established and caller therapeutics to code unmet aesculapian needs successful ophthalmology. Its strategical collaborations and diversified pipeline presumption it to vie successful the high-growth ophthalmic pharmaceutical market.

Read Entire Article